The University of Chicago Header Logo

Connection

Caner Saygin to Aged

Back to Details
This is a "connection" page, showing publications Caner Saygin has written about Aged.
Caner Saygin
Connection Strength
0.582
Aged
  1. Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis. Blood Cancer Discov. 2024 May 01; 5(3):164-179.
    View in: PubMed
    Score: 0.070
  2. Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq. Leukemia. 2021 12; 35(12):3406-3420.
    View in: PubMed
    Score: 0.057
  3. Therapy for lower-risk MDS. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):426-433.
    View in: PubMed
    Score: 0.055
  4. A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Am J Hematol. 2020 12; 95(12):1457-1465.
    View in: PubMed
    Score: 0.054
  5. Outcomes of the cyclophosphamide, vincristine, prednisone (CVP) +/- rituximab (R-CVP) regimen in older patients with newly diagnosed Ph- acute lymphoblastic leukemia. Leuk Res. 2020 02; 89:106297.
    View in: PubMed
    Score: 0.052
  6. Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. Blood Adv. 2019 12 23; 3(24):4228-4237.
    View in: PubMed
    Score: 0.052
  7. Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. Blood Cancer J. 2018 01 10; 8(1):4.
    View in: PubMed
    Score: 0.045
  8. Impact of comorbidities on outcomes of elderly patients with diffuse large B-cell lymphoma. Am J Hematol. 2017 Oct; 92(10):989-996.
    View in: PubMed
    Score: 0.044
  9. Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response. Leuk Lymphoma. 2018 02; 59(2):363-371.
    View in: PubMed
    Score: 0.043
  10. Risk prediction for clonal cytopenia: multicenter real-world evidence. Blood. 2024 Nov 07; 144(19):2033-2044.
    View in: PubMed
    Score: 0.018
  11. Impact of Age on Pharmacogenomics and Treatment Outcomes of B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2024 Oct 10; 42(29):3478-3490.
    View in: PubMed
    Score: 0.018
  12. Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms. Blood Cancer J. 2024 06 18; 14(1):99.
    View in: PubMed
    Score: 0.018
  13. Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy. Leuk Lymphoma. 2024 Jun; 65(6):864-867.
    View in: PubMed
    Score: 0.017
  14. Thy-1 predicts poor prognosis and is associated with self-renewal in ovarian cancer. J Ovarian Res. 2019 Nov 17; 12(1):112.
    View in: PubMed
    Score: 0.013
  15. Genomic determinants of chronic myelomonocytic leukemia. Leukemia. 2017 12; 31(12):2815-2823.
    View in: PubMed
    Score: 0.011
  16. Expression of MMP-1, MMP-9 and TIMP-2 in prostate carcinoma and their influence on prognosis and survival. J Cancer Res Clin Oncol. 2013 Aug; 139(8):1373-82.
    View in: PubMed
    Score: 0.008
  17. Primary central nervous system lymphoma in immunocompetent individuals: a single center experience. Int J Clin Exp Pathol. 2013; 6(6):1068-75.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.